Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción VRAX?
El precio actual de VRAX es de $0.64, ha decreased un 0.62% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Virax Biolabs Group Ltd?
Virax Biolabs Group Ltd pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Virax Biolabs Group Ltd?
La capitalización bursátil actual de Virax Biolabs Group Ltd es $2.7M
